{
  "docId": "019de076-341d-707d-8f10-e094a3d9771c",
  "docSlug": "c0c2a81b97260bf20014943df2470872",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 39,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes before/after clinical photos and a comparative table against Mogamulizumab.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-341d-707d-8f10-e094a3d9771c/20",
  "deckHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c",
  "deckJsonHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json",
  "deckAnchorHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.92,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Favorable safety and tolerability demonstrated in 93 subjects across populations with compelling clinical activity observed in CTCL patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5f7295c-bd40-4511-81fe-0041ee82f509",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.5,
        "x": 0.46,
        "y": 0.64
      },
      "kind": "image",
      "text": "Before and after clinical photos showing skin improvement at Week 1 vs Week 16",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5bda0e99-62aa-4af1-aafb-b1e0c46529a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "list",
      "text": "Heavily pre-treated, refractory patient population (median of 5 prior systemic treatments)\nDose escalation (0.5, 1, 2, 4mg/kg) with 4-week treatment/assessment period (n=30) followed by 12+ week extension (n=19)\nNo drug related SAEs, no DLTs and no clinically significant laboratory abnormalities\nDose-dependent PK/PD correlated with improved skin scores (mSWAT)\n2mg/kg was selected dose for study expansion and extension",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "898ff745-78db-4370-94af-9ac139877f4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1) Kim et al., Lancet Oncol., 2018. 2) Querfeld et al., Blood, 2019. mSWAT = modified severity-weighted assessment CTCL = Cutaneous T cell Lymphoma",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f7c578e-d57d-4da2-8a9c-6e70fc2364b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.5,
        "x": 0.46,
        "y": 0.345
      },
      "kind": "table",
      "text": "Response Rate in Stage IB/II Patients; MAVORIC Phase 3 Trial; EQ101 Phase 1/2; Mogamulizumab (n=68); EQ101 (n=19); 27.9%; 42.1%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ad3c1cf-0e54-4c7c-812e-a320937dfaaa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.87,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "EQ101: Clinically Validated in Severe Dermatological Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0272fcce-3eaf-4646-954b-af37d50f7c7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.04,
        "y": 0.345
      },
      "kind": "title",
      "text": "Phase 1/2 MAD study in Cutaneous T Cell Lymphoma (n=30)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "070566f0-5dce-4a98-9dcf-ee0a4da8406a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "b2af77ee-52be-4c5c-b7fe-1286b70a6a78",
      "evidence": "image/photo: Before and after clinical photos showing skin improvement at Week 1 vs Week 16",
      "confidence": 0.7
    },
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "03733fe1-99ca-493b-a9b8-256bd836b992",
      "evidence": "Favorable safety and tolerability demonstrated in 93 subjects across populations with compelling clinical activity observed in CTCL patients",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 20,
      "beatId": "17f2549b-60e8-4ea8-b75d-3f3cfbce32a9",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Traction is highlighted on pages 20-21.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}